AnaptysBio, Inc. · NASDAQ:ANAB
AnaptysBio — Technical Presentation (May 2024)
4 slides from AnaptysBio's technical presentation, May 2024
Slide 1: ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation in GvHD Model
055 ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease (GvHD) Eric Hare, Matthew Hsu, Cheryl Schendel, Chris Haines, Pejman Soroosh, Stephen Parmley, Martin Dahl, Paul L
Slide 2: BTLA is a Key Node of Immune Regulation and Target for ANB032
BTLA is a Key Node of Immune Regulation and Target for ANB032 B and T Lymphocyte Attenuator (BTLA): Potent modulator of T cells, B cells, and dendritic cells Proposed Mechanism of Action for ANB032 ANB032: IgG4 antibody (non-depleting) • Binds to BTLA on membrane proximal epitope • Fc receptor bindi
Slide 3: ANB032 was Efficacious in a Preclinical Model of GvHD
ANB032 was Efficacious in a Preclinical Model of GvHD Evaluating the Contribution of Both Epitope Binding and FcR Engagement to Efficacy In Vivo In vivo ANB032 Treatment Resulted in: • Prolonged survival • Maintenance of body weight • Reduced Disease Activity Index • Reduced human T cell expansion •
Slide 4: ANB032 Reduced Th1, Th2, Th17, and Th22 Cytokine Secretion in Atopic Dermatitis PBMCs
ANB032 Reduced Th1, Th2, Th17, and Th22 Cytokine Secretion in Atopic Dermatitis (AD) Patient-Derived PBMCs In Vitro Conclusion • BTLA agonism by ANB032 targets key cell types involved in the pathogenesis of atopic dermatitis • Preclinical in-vitro and in-vivo data support clinical development • ANB0